跳至主要内容
临床试验/ISRCTN46576063
ISRCTN46576063已完成不适用

Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)

nited Bristol Healthcare Trust (UK)0 个研究点目标入组 40 人开始时间: 2008年4月16日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Patients with sight-threatening non-infectious posterior intraocular inflammation (PSII) who:
  • 1. Are unable to reduce their prednisone dose to less than 10 mg daily without disease relapse
  • 2. Require recurrent high dose steroid rescue for recurrent relapsing disease
  • 3. Have severe sight-threatening disease warranting immediate institution of combination immunotherapy (high dose prednisone and a second line agent)
  • 4. Are greater than or equal to 18 years old, either sex, and able to give informed consent

排除标准

  • 1. Pregnancy or lactation
  • 2. Female patients of child bearing age who are unwilling or unable to maintain effective birth control during the study
  • 3. Diabetes mellitus (except steroid induced)
  • 4. Significant and unstable renal disease (creatinine outside the local laboratories reference range on two consecutive occasions)
  • 5. Participating in another clinical trial or has been taking an investigational drug in the past 28 days
  • 6. Unlikely to comply with the visits scheduled in the protocol
  • 7. Live vaccinations within three months of study entry
  • 8. Previous adverse event associated with, or contra-indication to, either prednisolone or tacrolimus
  • 9. Concurrent use of other immunosuppressive or cytotoxic agents
  • 10. Previous tuberculosis
  • 11. Shingles within the past three months
  • 12. Human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), including current or previous history of opportunistic infections such as cytomegalovirus (CMV), active Pneumocystis carinii, atypical mycobacterium
  • 13. Recent history of substance abuse (drug or alcohol)
  • 14. Use of cyclosporin A within the last three months
  • 15. Serious infections, such as hepatitis, pneumonia, pyelonephritis in the previous three months

研究者

发起方
nited Bristol Healthcare Trust (UK)

相似试验